LYMDEVRA

What this means for you

Approved and waiting on proof of use. It will register unless the applicant drops it, and its 21 Oct 2025 filing date already counts against anyone who files later.

Record

Serial number

99454183

Mark type

Stylized text

Filed

21 Oct 2025

Published for opposition

14 Apr 2026

Attorney of record

Maury M. Tepper, III

Goods and services

• Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Biological preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations containing viral vectors for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations based on morpholino oligomer technology platform for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Pharmaceutical preparations that modulate RNA expression for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Gene therapy products, namely, gene delivery pharmaceuticals for treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations for gene therapy, gene editing, and genome editing for treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Gene therapies, in the nature of pharmaceutical preparations, for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations, biological preparations and gene therapy products in the nature of pharmaceutical and biological preparations for the treatment of genetic disorders and diseases

Owner

• Sarepta Therapeutics, Inc., Cambridge, MA, US

Prosecution history

• 20 Mar 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
• 07 Mar 2026 — ASSIGNED TO EXAMINER
• 21 Oct 2025 — APPLICATION FILING RECEIPT MAILED
• 21 Oct 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
• 21 Oct 2025 — NEW APPLICATION ENTERED